EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial

Jae Yong Park, Su Jin Hong, Il Ju Choi, Gwang Ho Baik, Sun Moon Kim, Jong-Jae Park, Seong Woo Jeon, Kyung-Oh Kim, Sang Kil Lee, Hwoon-Yong Jung iD, Jung-Hwan Oh, Chan Hyuk Park und 8 weitere

Helicobacter · 2026

DOI: 10.1111/hel.70106 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2026. Verfasst von Jae Yong Park und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents, Proton Pump Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HK inno.N Corp..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tegoprazan, a potassium‐competitive acid blocker, offers potent and sustained acid inhibition and potentially improves eradication efficacy.

Aim

This study aimed to evaluate the efficacy and safety of tegoprazan‐based triple therapy with two dosing regimens compared with that of lansoprazole‐based therapy for first‐line Helicobacter pylori eradication.

Methods

This randomized, double‐blind, active‐controlled, multicenter trial was conducted at 19 referral hospitals in South Korea (February 2023–April 2024). Treatment‐naïve adults with H. pylori infection were randomized 1:1:1 to receive 14‐day triple therapy with tegoprazan, 50 mg (TAC1), tegoprazan, 100 mg (TAC2), or lansoprazole, 30 mg (LAC), each combined with amoxicillin 1000 mg and clarithromycin 500 mg, administered twice daily. The primary endpoint was H. pylori eradication rate in the modified intention‐to‐treat (mITT) population, with a non‐inferiority margin of −10%. Secondary endpoints included subgroup analyses based on clarithromycin resistance and safety assessments.

Results

Of the 564 screened patients, 382 were randomized. In the mITT analysis (mean age, 54.9 years; 54.3% male), eradication rates were 86.0%, 85.5%, and 78.7% for TAC1, TAC2, and LAC, respectively. Both tegoprazan‐based regimens met the non‐inferiority criteria. Among clarithromycin‐resistant infections, the eradication rates were higher for TAC1 (47.8%) and TAC2 (50.0%) than for LAC (35.5%), although the difference was not statistically significant. Safety profiles were comparable across the groups, with no serious drug‐related adverse events.

Conclusion

Tegoprazan‐based triple therapies, at 50‐ and 100‐mg doses, were non‐inferior to lansoprazole‐based therapy and were well tolerated. Our findings indicated that tegoprazan‐based triple therapy is a viable first‐line option for H. pylori eradication. Trial Registration ClinicalTrials.gov identifier: NCT05933031

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsProton Pump InhibitorsHumansMiddle AgedMaleFemaleDrug Therapy, CombinationDouble-Blind MethodAdultClarithromycinAmoxicillinLansoprazoleTreatment OutcomeAgedRepublic of Korea

Stichwörter der Autor:innen

Helicobacter pylorieradicationpotassium‐competitive acid blockerrandomized clinical trialstegoprazan

Substanzen

Anti-Bacterial AgentsClarithromycinAmoxicillinLansoprazoleProton Pump Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
  • Center for Gastric Cancer, National Cancer Center, Goyang, Republic of Korea.
  • Department of Internal Medicine, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Republic of Korea.
  • Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Hwoon-Yong Jung, Jae Gyu Kim

Förderung

  • HK inno.N Corp.

Zitieren

APA

Park, J. Y., Hong, S. J., Choi, I. J., Baik, G. H., Kim, S. M., Park, J. J., Jeon, S. W., Kim, K. O., Lee, S. K., Jung, H. Y., Oh, J. H., Park, C. H., Kim, S. W., Shim, K. N., Jee, S. R., Moon, H. S., Moon, J. S., Choi, C. W., Lee, W. S., & Kim, J. G. (2026). Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. Helicobacter. https://doi.org/10.1111/hel.70106

Vancouver

Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ, et al. Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. Helicobacter. 2026. doi:10.1111/hel.70106

BibTeX
@article{Park2026,
  author = {Park, Jae Yong and Hong, Su Jin and Choi, Il Ju and Baik, Gwang Ho and Kim, Sun Moon and Park, Jong-Jae and Jeon, Seong Woo and Kim, Kyung-Oh and Lee, Sang Kil and Jung, Hwoon-Yong and Oh, Jung-Hwan and Park, Chan Hyuk and Kim, Sang Wook and Shim, Ki-Nam and Jee, Sam Ryong and Moon, Hee Seok and Moon, Jeong Seop and Choi, Cheol Woong and Lee, Wan-Sik and Kim, Jae Gyu},
  title = {Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70106}
}
Kostenlos starten →